RSRashmi Sood

Rashmi Sood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rashmi Sood has a total of 132 co-authors. Here are the top co-authors by number of shared publications:

  • Hartmut Weiler

    Blood Research Institute, BloodCenter of Wisconsin, Milwaukee WI

    8 shared publications
  • Mark Zogg

    Blood Research Institute, BloodCenter of Wisconsin, Milwaukee WI

    5 shared publications
  • Min Zhan

    Division of Pediatric Pathology, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA

    4 shared publications
  • Qiuhui Yang

    Division of Pediatric Pathology, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA

    4 shared publications
  • Berend Isermann

    Blood Research Institute, BloodCenter of Wisconsin, Milwaukee

    3 shared publications
  • Edward J. Kerschen

    Blood Research Institute, BloodCenter of Wisconsin, Milwaukee

    3 shared publications

Latest Publications

  • Open Access

    The endothelial protein C receptor plays an essential role in the maintenance of pregnancy

    by Michelle M. Castillo, Qiuhui Yang, Abril Solis Sigala, Dosia T. McKinney, Min Zhan, Kristen L. Chen, Jason A. Jarzembowski, Rashmi Sood

    Mice reveal a link between maternal or fetal thrombophilia, uteroplacental thrombosis, hemorrhage, and placental abruption.


  • Open Access

    The Endothelial Protein C Receptor plays an essential role in the maintenance of Pregnancy

    by Michelle M Castillo, Qiuhui Yang, Abril Solis Sigala, Dosia T McKinney, Min Zhan, Kristen L Chen, Jason A Jarzembowski, Rashmi Sood

    Placenta-mediated pregnancy complications are a major challenge in the management of maternal-fetal health. Maternal thrombophilia is a suspected risk factor but the role of thrombotic processes in these complications and the potential for antithrombotic treatment have remained unclear. Endothelial Protein C Receptor (EPCR) is an anticoagulant protein highly expressed in the placenta. EPCR autoantibodies and specific gene variants of EPCR are associated with poor pregnancy outcomes. In mice, fetal EPCR deficiency results in placental failure andin uterodeath. Adult EPCR-deficient mice generated by maintaining placental expression exhibit plasma markers of thrombophilia without overt thrombosis. We demonstrate that inactivation of clotting factor VIII or Protease Activated Receptor 4 (Par4), Par3 or integrin αIIb in the mother allows placental development and intrauterine survival of murine embryos lacking EPCR. Rescued EPCR-deficient embryos exhibit thrombosis in placental venous sinuses at late gestation and a high rate of neonatal lethality. In contrast to fetal EPCR deficiency, maternal deficiency of EPCR results in frequent stillbirths and maternal death accompanied by pathological findings that resemble placental abruption and consumptive coagulopathy. Inactivation of Par4, but not clotting factor VIII, prevents maternal death and restores normal pregnancy outcomes. These observations establish a cause-effect relationship between maternal thrombophilia and placental abruption. They demonstrate that sites of uteroplacental thrombosis and the potential response to antithrombotic intervention may differ with gestational age and maternal versus fetal origin of thrombophilia. Our findings highlight the potential for therapeutic inhibition of thrombin-mediated platelet activation in a subset of pregnancy complications.KEY POINTS: Murine model establishes a cause-effect relationship between maternal thrombophilia, retroplacental hemorrhage and severe pregnancy complications. Thrombin-mediated activation of maternal platelets is a key event in thrombophilia-associated pregnancy complications and a potential target of therapeutic intervention. Maternal venous channels in uteroplacental circulation are additional sites of thrombotic pathology associated with adverse neonatal outcomes.

  • Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency

    by Michelle M. Castillo, Qiuhui Yang, Min Zhan, Amy Y. Pan, Michael W. Lawlor, Alan E. Mast, Rashmi Sood

    Tissue factor pathway inhibitor (TFPI) is a serine protease with multiple anticoagulant activities. The Kunitz1 (K1) domain of TFPI binds the active site of factor VIIa and is required for inhibition of tissue factor (TF)/factor VIIa catalytic activity. Mice lacking TFPI K1 domain die in utero. TFPI is highly expressed on trophoblast cells of the placenta. We used genetic strategies to selectively ablate exon 4 encoding TFPI K1 domain in the embryo, while maintaining expression in trophoblast cells. This approach resulted in expected Mendelian frequency of TFPI K1 domain–deficient mice. Real-time polymerase chain reaction confirmed 95% to 99% genetic deletion and a similar reduction in transcript expression. Western blotting confirmed the presence of a truncated protein instead of full-length TFPI. Mice with severe TFPI K1 deficiency exhibited elevated thrombin-antithrombin (TAT) levels, frequent fibrin deposition in renal medulla, and increased susceptibility to TF-induced pulmonary embolism. They were fertile, and most lived normal life spans without any overt thrombotic events. Of 43 mice observed, 2 displayed extensive brain ischemia and infarction. We conclude that in contrast to complete absence of TFPI K1 domain, severe deficiency is compatible with in utero development, adult survival, and reproductive functions in mice. Inhibition of TFPI activity is being evaluated as a means of boosting thrombin generation in hemophilia patients. Our results show that in mice severe reduction of TFPI K1 activity is associated with a prothrombotic state without overt developmental outcomes. We note fibrin deposits in the kidney and rare cases of brain ischemia.


  • Open Access

    Humanized GPIbα–von Willebrand factor interaction in the mouse

    by Sachiko Kanaji, Jennifer N. Orje, Taisuke Kanaji, Yuichi Kamikubo, Yosuke Morodomi, Yunfeng Chen, Alessandro Zarpellon, Jerome Eberhardt, Stefano Forli, Scot A. Fahs, et al.

    The interaction of platelet glycoprotein Ibα (GPIbα) with von Willebrand factor (VWF) initiates hemostasis after vascular injury and also contributes to pathological thrombosis. GPIbα binding to the VWF A1 domain (VWFA1) is a target for antithrombotic intervention, but attempts to develop pharmacologic inhibitors have been hindered by the lack of animal models because of the species specificity of the interaction. To address this problem, we generated a knockin mouse with Vwf exon 28–encoding domains A1 and A2 replaced by the human homolog (VWFh28). VWFh28 mice (M1HA) were crossbred with a transgenic mouse strain expressing human GPIbα on platelets (mGPIbαnull;hGPIbαTg; H1MA) to generate a new strain (H1HA) with humanized GPIbα-VWFA1 binding. Plasma VWF levels in the latter 3 strains were similar to those of wild-type mice (M1MA). Compared with the strains that had homospecific GPIbα-VWF pairing (M1MA and H1HA), M1HA mice of those with heterospecific pairing had a markedly greater prolongation of tail bleeding time and attenuation of thrombogenesis after injury to the carotid artery than H1MA mice. Measurements of GPIbα-VWFA1 binding affinity by surface plasmon resonance agreed with the extent of observed functional defects. Ristocetin-induced platelet aggregation was similar in H1HA mouse and human platelet-rich plasma, and it was comparably inhibited by monoclonal antibody NMC-4, which is known to block human GPIbα-VWFA1 binding, which also inhibited FeCl3-induced mouse carotid artery thrombosis. Thus, the H1HA mouse strain is a fully humanized model of platelet GPIbα-VWFA1 binding that provides mechanistic and pharmacologic information relevant to human hemostatic and thrombotic disorders.


  • Variable phenotypic penetrance of thrombosis in adult mice after tissue-selective and temporally controlled Thbd gene inactivation

    by Thijs E. van Mens, Hai-Po H. Liang, Sreemanti Basu, Irene Hernandez, Mark Zogg, Jennifer May, Min Zhan, Qiuhui Yang, Jamie Foeckler, Shawn Kalloway, et al.

    Thrombomodulin (Thbd) exerts pleiotropic effects on blood coagulation, fibrinolysis, and complement system activity by facilitating the thrombin-mediated activation of protein C and thrombin-activatable fibrinolysis inhibitor and may have additional thrombin- and protein C (pC)-independent functions. In mice, complete Thbd deficiency causes embryonic death due to defective placental development. In this study, we used tissue-selective and temporally controlled Thbd gene ablation to examine the function of Thbd in adult mice. Selective preservation of Thbd function in the extraembryonic ectoderm and primitive endoderm via the Meox2Cre-transgene enabled normal intrauterine development of Thbd-deficient (Thbd−/−) mice to term. Half of the Thbd−/− offspring expired perinatally due to thrombohemorrhagic lesions. Surviving Thbd−/− animals only rarely developed overt thrombotic lesions, exhibited low-grade compensated consumptive coagulopathy, and yet exhibited marked, sudden-onset mortality. A corresponding pathology was seen in mice in which the Thbd gene was ablated after reaching adulthood. Supplementation of activated PC by transgenic expression of a partially Thbd-independent murine pC zymogen prevented the pathologies of Thbd−/− mice. However, Thbd−/− females expressing the PC transgene exhibited pregnancy-induced morbidity and mortality with near-complete penetrance. These findings suggest that Thbd function in nonendothelial embryonic tissues of the placenta and yolk sac affects through as-yet-unknown mechanisms the penetrance and severity of thrombosis after birth and provide novel opportunities to study the role of the natural Thbd-pC pathway in adult mice and during pregnancy. Key Points Thrombomodulin deficiency in adult mice induces a fatal coagulopathy caused by the lack of cofactor function for activation of protein C. The severity of thrombosis after birth is modulated by in utero thrombomodulin expression in extraembryonic tissues. Visual Abstract


  • Vasculogenesis and Angiogenesis

    by Chang Zoon Chun, Rashmi Sood, Ramani Ramchandran


  • Heparin rescues factor V Leiden–associated placental failure independent of anticoagulation in a murine high-risk pregnancy model

    by Jianzhong An, Magarya S. Waitara, Michelle Bordas, Vidhyalakshmi Arumugam, Raymond G. Hoffmann, Brian G. Petrich, Uma Sinha, Paula E. North, Rashmi Sood

    Key Points: Heparin may have beneficial effects on placental health beyond anticoagulation. Thrombin receptor activation on maternal platelets is implicated in placental developmental failure independent of thrombosis.


  • Open Access

    Thrombophilia and fetal loss: Lessons from gene targeting in mice

    by Rashmi Sood, Katharine L. Cheung, Beth A. Bouchard, Mary Cushman


  • Caveolin-1–dependent apoptosis induced by fibrin degradation products

    by Yi-He Guo, Irene Hernandez, Berend Isermann, Tae-Bong Kang, Leonid Medved, Rashmi Sood, Edward J. Kerschen, Trudy Holyst, Michael W. Mosesson, Hartmut Weiler

    In mice lacking the blood coagulation regulator thrombomodulin, fibrinolytic degradation products (FDP) of fibrin induce apoptotic cell death of a specialized cell type in the placenta, polyploid trophoblast giant cells. Here, we document that this bioactivity of FDP is conserved in human FDP, is not limited to trophoblast cells, and is associated with an Aα-chain segment of fibrin fragment E (FnE). The majority of proapoptotic activity is arginine-glycine-aspartic acid (RGD)-independent and requires caveolin-1–dependent cellular internalization of FnE. Internalization through caveoli is mediated by an epitope contained within Aα52-81 that is necessary and sufficient for cellular uptake of FnE. Aα52-81 does not cause apoptosis itself, and competitively inhibits FnE internalization and apoptosis induction. Apoptotic activity per se resides within Aα17-37 and requires the N-terminal neoepitope generated by release of fibrinopeptide A. Cellular internalization of FnE elicits depression of mitochondrial function and consequent apoptosis that is strictly dependent on the activity of caspases 9 and 3. These findings describe the molecular details of a novel mechanism linking fibrin degradation to cell death in the placenta, which may also contribute to pathologic alterations in nonplacental vascular beds that are associated with fibrinolysis.